Literature DB >> 21219589

The assessment of aspirin resistance by using light transmission and multiple electrode aggregometry.

J Ulehlova1, L Slavik, V Krcova, M Hutyra, J Galuszka, K Indrak.   

Abstract

INTRODUCTION: The issues related to aspirin [acetylsalicylic acid (ASA)] resistance are still under debate. Depending on the method of assessment and studied patients, the prevalence of ASA resistance is rather heterogeneous, ranging from 5% to 45%. The method most commonly used for assessing platelet function is their aggregation. ASA irreversibly inhibits cyclooxygenase-1 (COX-1) by acetylation.
METHODS: This study aimed to compare light transmission aggregometry (LTA) and multiple electrode aggregometry (MEA) for the measurement of ASA resistance, using arachidonic acid as an inducer of the reaction.
RESULTS: The study comprised 101 patients with stable ischemic heart disease taking a daily dose of 100 mg of ASA. The rates of ASA resistance were 22.22% and 21.21% as detected by LTA and MEA, respectively. The two methods were statistically compared using Spearman's nonparametric correlation analysis, with a positive significant correlation (P=0.01) and medium positive dependence between the methods (r=0.0539).
CONCLUSION: If ASA resistance is detected by laboratory tests, replacement of ASA or its combination with other antiplatelet drugs as well as increased dosage may be considered.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21219589     DOI: 10.1111/j.1751-553X.2010.01286.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  2 in total

1.  Genetic polymorphisms of platelet receptors in patients with acute myocardial infarction and resistance to antiplatelet therapy.

Authors:  Jana Ulehlova; Ludek Slavik; Jana Kucerova; Vera Krcova; Jan Vaclavik; Karel Indrak
Journal:  Genet Test Mol Biomarkers       Date:  2014-08-05

2.  Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial.

Authors:  Christian Schoergenhofer; Eva-Luise Hobl; Michael Schwameis; Georg Gelbenegger; Thomas Staudinger; Gottfried Heinz; Walter S Speidl; Christian Zauner; Birgit Reiter; Irene Lang; Bernd Jilma
Journal:  Eur J Clin Invest       Date:  2017-06-20       Impact factor: 4.686

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.